Four interconnected projects, each asking a different question about the same underlying problem: why some tumours respond to treatment, and why others don't.
Molecular Oncology
Investigating how stromal cells and immune infiltrates shape disease progression in TNBC using spatial transcriptomics and multiplexed imaging across patient-derived tissue cohorts.
Biomarker Discovery
Developing a multi-analyte liquid biopsy panel combining cell-free DNA methylation signatures with extracellular vesicle proteomics to detect pancreatic adenocarcinoma at resectable stages.
Therapeutics
A high-throughput screen of clinically advanced kinase inhibitors against patient-derived glioblastoma stem cells, identifying synergistic combinations that overcome temozolomide resistance.
Immunology
Characterising the transcriptional and epigenetic programmes that drive CD8⁺ T-cell exhaustion in liver tumours, with the goal of restoring anti-tumour immunity through targeted reprogramming.
A reproducibility-first approach — every project combines wet-lab experimentation with version-controlled computational analysis.
2D cell lines, 3D spheroids and patient-derived organoids — chosen to mirror tumour biology, not just convenience.
RT-qPCR, Western blot, ELISA, multiplexed flow cytometry, CRISPR perturbations and bulk + single-cell sequencing.
Confocal, light-sheet and CODEX multiplexed imaging for the spatial context that bulk assays miss.
Reproducible pipelines in Nextflow / Snakemake, statistical modelling in R, and ML in Python — all version-controlled.
Grateful to the groups, clinicians and institutions whose data, samples, time and patience make this work possible.